Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Phase 3
Recruiting
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000001537
- Lead Sponsor
- Wakayama Medical University, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with other cancer requiring treatment 2. Patients with serious complications 3. Patients who fall under the following(Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL, AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum Creatinine > 1.5 times ULN)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biochemical progression-free survival (PFS)
- Secondary Outcome Measures
Name Time Method Overall survival Cause- specific survival Clinical progression-free survival QOL Safety